The Technical Signals Behind (TBPH) That Institutions Follow
This article from Stock Traders Daily analyzes the technical signals for Theravance Biopharma Inc. (NASDAQ: TBPH) that institutional investors typically follow. It highlights divergent sentiment across different time horizons, weak near-term outlook, but strong long-term potential, with support being tested. The article provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Navigating a 37.70% Potential Upside in Biotechnology
Theravance Biopharma, Inc. (TBPH) offers a compelling investment opportunity in the biotechnology sector, identified by a potential upside of 37.70% according to analyst targets. The company, known for its COPD medication YUPELRI and pipeline product Ampreloxetine, demonstrates strong revenue growth of 18.50% and a positive outlook from analysts. With its stock trading above moving averages and a reasonable forward P/E ratio, TBPH is positioned for future growth through innovation and strategic partnerships.
Baader Bank Aktiengesellschaft Invests $781,000 in Theravance Biopharma, Inc. $TBPH
Baader Bank Aktiengesellschaft recently acquired a new stake of 53,500 shares, valued at approximately $781,000, in Theravance Biopharma, Inc. (NASDAQ:TBPH). Other institutional investors also adjusted their holdings in the biopharmaceutical company, which has seen varied analyst ratings with an average "Buy" consensus and a target price of $27.80. Meanwhile, Theravance's SVP Rhonda Farnum sold a portion of her shares, and the company reported stronger-than-expected earnings in its last quarter.
Theravance Biopharma Inc (NASDAQ:TBPH) Shows Strong Technical and Fundamental Momentum
Theravance Biopharma Inc (NASDAQ:TBPH) displays strong technical and fundamental momentum, aligning with Mark Minervini's stock selection strategy. The company's stock currently trades above key moving averages, is near its 52-week high, and exhibits superior relative strength. Fundamentally, Theravance Biopharma shows significant quarterly earnings and revenue growth, along with positive analyst revisions and increasing free cash flow.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Buy" from Brokerages
Theravance Biopharma, Inc. (NASDAQ:TBPH) has received an average "Buy" rating from seven analysts, with an average 12-month price target of $27.80. Insider selling activity was noted, with SVP Rhonda Farnum selling 31,067 shares. The company recently beat Q3 EPS estimates, and institutional investors have been actively trading its shares.
Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones
This article details a precision trading analysis for Theravance Biopharma Inc. (TBPH), highlighting a 40.6:1 risk-reward setup targeting a 10.7% gain against a 0.3% risk. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide traders on entry, target, and stop-loss zones. The analysis suggests a near-term strong sentiment, a mid-term neutrality, and a long-term positive bias for TBPH.
Theravance Biopharma's (TBPH) "Buy" Rating Reaffirmed at BTIG Research
BTIG Research has reiterated a "Buy" rating for Theravance Biopharma (TBPH) with a $40.00 target price, indicating a potential upside of over 100%. This re-affirmation comes after the biopharmaceutical company reported an earnings beat, with EPS of $0.07 against an expected -$0.03. The stock is currently trading near its 12-month high, at around $19.83, and institutional investors hold a significant majority of the shares.
While shareholders of Theravance Biopharma (NASDAQ:TBPH) are in the black over 1 year, those who bought a week ago aren't so fortunate
Theravance Biopharma (NASDAQ:TBPH) shareholders have seen a significant return of 98% over the past year, outperforming the market, and a 79% increase over three years. The company recently transitioned from a loss to profitability, with a 27% revenue growth. Despite strong long-term performance, the stock has experienced a 6.6% pullback in the last week.
While shareholders of Theravance Biopharma (NASDAQ:TBPH) are in the black over 1 year, those who bought a week ago aren't so fortunate
Theravance Biopharma (NASDAQ:TBPH) shareholders have seen significant returns over the last year, with the stock appreciating by 98%, far exceeding the general market. The company recently transitioned from a loss to profitability and demonstrated a strong revenue growth of 27%. Despite a recent short-term pullback, the long-term performance and improved fundamentals suggest a positive outlook for the biopharmaceutical company.
While shareholders of Theravance Biopharma (NASDAQ:TBPH) are in the black over 1 year, those who bought a week ago aren't so fortunate
Theravance Biopharma, Inc. (NASDAQ:TBPH) has seen its share price increase by 98% over the last year, outperforming the market's 14% return. This positive trend extends to a 79% increase over three years, demonstrating strong long-term performance. The company has also transitioned from reporting a loss to a profit in the past year, complemented by a 27% revenue growth.
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?
The options market is showing high implied volatility for Theravance Biopharma (TBPH) stock, particularly for the March 20, 2026 $10 Put, suggesting expectations for a significant price movement. Despite this, analysts currently rate TBPH as a Zacks Rank #3 (Hold), with recent earnings estimate revisions being slightly negative. This high implied volatility might indicate a potential trading opportunity for options traders who sell premium.
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above Fifty Day Moving Average - Here's What Happened
Theravance Biopharma (NASDAQ:TBPH) saw its share price rise above its 50-day moving average, trading as high as $20.02. The company reported strong quarterly earnings, beating analyst expectations, and several analysts have issued "Buy" ratings with an average price target of $27.80. Insider ownership stands at approximately 6.9%, with institutional investors and hedge funds holding 99.10% of the stock.
Technical Reactions to TBPH Trends in Macro Strategies
This article analyzes Theravance Biopharma Inc. (NASDAQ: TBPH) using AI models, indicating strong sentiment across all horizons and an overweight bias. It highlights that resistance is being tested and presents three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Theravance Biopharma stock hits 52-week high at $21.01 By Investing.com
Theravance Biopharma (TBPH) stock recently reached a new 52-week high of $21.01, reflecting a 117.63% price return over the past year and strong investor confidence. The company's financial health is robust, with a current ratio of 9.48 and a "GREAT" overall financial health score from InvestingPro, although it is considered overvalued compared to its Fair Value. Recent positive developments include surpassing Q3 2025 earnings expectations, a 19% increase in collaboration revenue, and an "Outperform" rating from Oppenheimer due to the potential of its ampreloxetine treatment.
Theravance Biopharma stock hits 52-week high at $21.01
Theravance Biopharma Inc. (TBPH) stock recently hit a new 52-week high of $21.01, reflecting strong investor confidence with a 1-year price return of 117.63%. The company, valued at $1.06 billion, has shown impressive gains and maintains a robust financial position with a current ratio of 9.48. Despite being considered overvalued by InvestingPro, analysts anticipate further upside, with one firm initiating coverage with an Outperform rating and a $27 price target, citing potential in its ampreloxetine treatment.
Theravance Biopharma stock hits 52-week high at 20.69 USD
Theravance Biopharma (TBPH) stock has reached a new 52-week high of $20.69, reflecting strong investor confidence and solid fundamentals. The company boasts "GREAT" financial health and a 138.34% increase in stock price over the last year, driven by impressive revenue growth and exceptional liquidity. Recent earnings surpassed expectations, and Oppenheimer initiated coverage with an Outperform rating, citing the potential of its ampreloxetine treatment.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts
Analysts have given Theravance Biopharma, Inc. (NASDAQ:TBPH) a consensus "Buy" rating, with an average 12-month price target of $27.80. The company reported strong quarterly earnings, beating analyst expectations, and its stock has shown positive price performance recently. However, a senior vice president recently sold a significant number of shares, and while institutional investors hold a large stake, insider ownership is 6.90%.
Theravance Biopharma stock hits 52-week high at 20.69 USD By Investing.com
Theravance Biopharma (TBPH) stock recently hit a 52-week high of $20.69, reflecting strong investor confidence and solid financial health with a "GREAT" rating from InvestingPro. The company has seen a 138.34% increase in stock price over the past year and boasts strong revenue growth and liquidity. Recent news includes beating Q3 2025 earnings expectations, an "Outperform" rating from Oppenheimer, and plans for an investor event to discuss its Phase 3 clinical program.
Theravance Biopharma stock hits 52-week high at 20.69 USD By Investing.com
Theravance Biopharma's stock has reached a 52-week high of $20.69, reflecting strong investor confidence and a 138.34% increase over the past year. The company boasts a "GREAT" financial health score, impressive revenue growth, and exceptional liquidity. Recent positive news includes exceeding earnings expectations and Oppenheimer initiating coverage with an Outperform rating.
Trading the Move, Not the Narrative: (TBPH) Edition
This article provides an AI-generated analysis for Theravance Biopharma Inc. (TBPH), highlighting strong sentiment across all horizons and an ongoing breakout. It details institutional trading strategies including long, momentum breakout, and short positions, along with multi-timeframe signal analysis, to guide trading decisions based on technical indicators rather than subjective narratives.
Theravance Biopharma, Inc. Announces Upcoming Phase 3 Data for Ampreloxetine
Theravance Biopharma, Inc. (TBPH) announced that Phase 3 data for Ampreloxetine, a drug targeting symptomatic neurogenic orthostatic hypotension in MSA patients, is expected in Q1 2026. The company highlights its strong financial position with $333 million in cash and no debt as of Q3 2025, along with a commitment to return excess capital to shareholders. This announcement was initially made via an 8-K SEC filing on January 12, 2026.
Theravance Biopharma (NASDAQ:TBPH) Lowered to Buy Rating by Wall Street Zen
Wall Street Zen downgraded Theravance Biopharma (NASDAQ:TBPH) from a "strong-buy" to a "buy" rating, while the analyst consensus remains a "Buy" with an average price target of $27.80. The company recently reported an EPS beat for the quarter, and insiders own 6.9% of the company's stock. Several institutional investors have also modified their holdings in TBPH.
Can Theravance Biopharma's Ampreloxetine Fill The Gap In MSA-Related NOH Therapy?
Theravance Biopharma (TBPH) is awaiting pivotal trial results this quarter for ampreloxetine, a potential first-in-class treatment for neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Current treatments for MSA-related nOH are often insufficient, creating a significant need for new therapies. The company also generates substantial revenue from its partnership with Viatris for the COPD treatment YUPELRI.
Inspire Investing LLC Purchases New Position in Theravance Biopharma, Inc. $TBPH
Inspire Investing LLC has acquired a new stake of 73,556 shares, valued at approximately $1.074 million, in Theravance Biopharma (NASDAQ:TBPH) during the third quarter, bringing their ownership to 0.15%. This comes as Theravance Biopharma reported strong quarterly earnings, beating expectations with EPS of $0.07. Institutional investors collectively hold 99.10% of the biopharmaceutical company's stock, and analysts maintain a "Buy" consensus rating with an average price target of $27.80.
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade
Wall Street analysts project a potential 42.2% upside for Theravance Biopharma (TBPH) shares, with a mean price target of $26.71. While price targets are not always reliable indicators, the strong agreement among analysts in revising EPS estimates higher suggests a potential rally. The stock currently holds a Zacks Rank #2 (Buy), further indicating its near-term upside potential.
Assenagon Asset Management S.A. Boosts Position in Theravance Biopharma, Inc. $TBPH
Assenagon Asset Management S.A. significantly increased its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 1,629.4% in the third quarter of 2025, now owning 414,715 shares valued at approximately $6.06 million. Several other institutional investors also adjusted their positions in the company. Theravance Biopharma reported strong Q3 earnings, beating analyst expectations, and maintains an average "Buy" rating from analysts with an average target price of $27.80.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Brokerages
Theravance Biopharma, Inc. (NASDAQ:TBPH) has received a consensus "Buy" recommendation from seven research firms, with an average one-year price target of $27.80. Insider Rhonda Farnum recently sold shares totaling over $582,000, while institutional investors hold approximately 99.10% of the company's stock. The company exceeded its latest quarterly EPS estimate and reported revenues of nearly $20 million, with analysts projecting a -1.09 EPS for the current fiscal year.
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Theravance Biopharma (NASDAQ:TBPH) from a "buy" to a "strong-buy" rating. This upgrade follows several other analysts' positive revisions, with the stock currently holding a "Buy" consensus rating and an average price target of $27.80. The company recently exceeded earnings expectations, reporting an EPS of $0.07 against an anticipated ($0.03).
Camber Capital Management LP Trims Stock Position in Theravance Biopharma, Inc. $TBPH
Camber Capital Management LP significantly reduced its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 55% during the second quarter, selling 550,000 shares and retaining 450,000 worth $4.96 million. Despite this, analysts largely maintain a "Buy" consensus with a target price of $27.80, and some firms have even increased their price targets or initiated
Hsbc Holdings PLC Takes Position in Theravance Biopharma, Inc. $TBPH
Hsbc Holdings PLC has acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH), purchasing 57,214 shares valued at approximately $638,000. This investment represents about 0.11% of the company. Institutional investors collectively own around 99.10% of TBPH, while analysts maintain an average "Buy" rating with a consensus price target of $27.80.
Theravance Biopharma schedules 2026 annual meeting and hosts investor event By Investing.com
Theravance Biopharma (NASDAQ:TBPH) announced it will hold its 2026 Annual General Meeting of Shareholders on June 12, 2026, in Dublin, Ireland. The company is also hosting a virtual key opinion leader investor event focused on ampreloxetine. These announcements follow a strong year for the biopharmaceutical company, which has seen a 97% return year-to-date and holds more cash than debt.
Theravance Biopharma schedules 2026 annual meeting and hosts investor event By Investing.com
Theravance Biopharma (NASDAQ:TBPH) has announced two upcoming corporate events: a virtual key opinion leader (KOL) investor event focused on ampreloxetine and its 2026 Annual General Meeting of Shareholders. The company, which has seen impressive year-to-date returns and strong financial health, recently reported a surprising Q3 2025 earnings beat and received an "Outperform" rating from Oppenheimer. These events highlight the company's continued progress in its clinical programs, particularly for ampreloxetine.
Rhonda Farnum Sells 31,067 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock
Rhonda Farnum, SVP of Theravance Biopharma (NASDAQ:TBPH), sold 31,067 shares of the company's stock on December 3rd, reducing her holding by over 10%. The sale was valued at approximately $582,506 and lowered her total stake to 277,695 shares. Despite this insider sale, analysts maintain a largely favorable outlook on TBPH, with a consensus "Buy" rating and an average price target of $27.80.
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
Theravance Biopharma (TBPH) shares have increased 25.8% recently, with Wall Street analysts predicting a potential 30.6% upside. This optimism is supported by a mean price target of $24.43 and strong agreement among analysts with upward revisions in EPS estimates, indicating potential near-term stock price movement despite general skepticism about analyst price targets.
Oppenheimer Initiates Theravance Biopharma at Outperform With $27 Price Target
Oppenheimer has initiated coverage of Theravance Biopharma (NASDAQ: TBPH) with an Outperform rating and a price target of $27. This positive outlook suggests confidence in the biopharmaceutical company's future performance. The company specializes in developing medicines, including YUPELRI for COPD and Ampreloxetine for neurogenic orthostatic hypotension.
Theravance Biopharma to Participate in Upcoming Investor Conferences
Theravance Biopharma, Inc. announced its management will participate in two upcoming investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference and the Oppenheimer Movers in Rare Disease Summit. The company will be available for one-on-one meetings at both events, and a live webcast of the Evercore presentation will be available on their website.
Revenues Not Telling The Story For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Shares Rise 32%
Theravance Biopharma's shares have surged by 32% in the last month, contributing to a 108% annual gain, yet its price-to-sales (P/S) ratio of 11.7x is significantly higher than the industry average. Despite impressive past revenue growth of 27% last year and 56% over three years, future revenue growth is estimated at 25% annually, which is weaker than the predicted 29% for the broader industry. The article suggests that the high P/S ratio is alarming given the less optimistic revenue forecasts, implying that the current stock prices might not be sustainable.
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. announced its third-quarter 2025 financial results, highlighted by record YUPELRI net sales of $71.4 million and achieving non-GAAP breakeven. The company is advancing ampreloxetine toward topline results from the pivotal Phase 3 CYPRESS study, expected in Q1 2026, and is on track to meet TRELEGY sales milestones. Theravance Biopharma ended the quarter with a strong balance sheet of $333 million in cash and no debt.
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy - BioSpace
Theravance Biopharma, Inc. has launched "Power in the Periphery," a disease education campaign aimed at healthcare professionals to enhance their understanding of neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA). The campaign seeks to raise awareness about the complex mechanisms underlying nOH, a serious disorder with debilitating symptoms that significantly disrupt daily life for MSA patients. This initiative debuted at the International Congress of Parkinson’s Disease and Movement Disorders® and highlights Theravance Biopharma's commitment to advancing education in specialty neurologic diseases.
Theravance Biopharma Launches MSA-Related nOH Education Campaign | TBPH Stock News - Stock Titan
Theravance Biopharma, Inc. (NASDAQ: TBPH) has launched "Power in the Periphery," a disease education campaign aimed at healthcare professionals to increase understanding of neurogenic orthostatic hypotension (nOH) associated with Multiple System Atrophy (MSA). The campaign highlights the complex mechanisms of nOH, a serious disorder prevalent in neurodegenerative conditions like MSA. Theravance Biopharma is committed to advancing education on this challenging condition that significantly impacts patients' daily lives.
Theravance Biopharma Hits New 52-Week High of $15.15, Up 67.59% - Markets Mojo
Theravance Biopharma, Inc. reached a new 52-week high of USD 15.15 on October 6, 2025, demonstrating strong performance in the pharmaceuticals sector. The company reported a significant 83.75% increase in net sales and a 67.59% rise in stock value over the past year, far outperforming the S&P 500. This milestone highlights its robust operational capabilities and strong institutional investor confidence.
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
Theravance Biopharma has completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Topline results are expected in Q1 2026, with plans for an expedited NDA submission if successful. Ampreloxetine has Orphan Drug Designation and aims to address a significant unmet medical need for the estimated 40,000 U.S. patients suffering from nOH due to MSA.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance Biopharma (TBPH) announced it will sell its remaining royalty interest in Trelegy Ellipta to GSK for $225 million in cash, with potential for an additional $150 million milestone payment from Royalty Pharma. This strategic move, aimed at maximizing shareholder value, led to a 22% surge in Theravance's stock. The company continues to focus on the commercialization of Yupelri and the development of ampreloxetine for neurogenic orthostatic hypotension.
Theravance Biopharma to Present at Evercore HealthCONx Conference
Theravance Biopharma (NASDAQ: TBPH) announced its participation in the 7th Annual Evercore HealthCONx Conference. The company will host a Fireside Chat on December 3rd at 11:15 am EST and conduct in-person meetings with the investment community. A webcast of the event will be available on Theravance.com and a replay will be accessible for 30 days.
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
Theravance Biopharma announced the publication of a sub-study in the International Journal of Chronic Obstructive Pulmonary Disease, detailing the lung function effects of YUPELRI® (revefenacin) in COPD patients. The analysis reinforced that YUPELRI provides consistent and durable improvements in lung function over 24 hours, with rapid onset of bronchodilation observed within 15 minutes. This data provides valuable clinical insight into the duration and consistency of revefenacin's therapeutic effects.
Beleaguered Theravance logs head-to-head trial loss for Yupelri against Boehringer's Spiriva
Theravance's bronchodilator Yupelri failed to show superior lung function improvement compared to Boehringer Ingelheim’s Spiriva in a head-to-head Phase 4 trial for COPD. This marks another setback for the company, following previous program terminations and staff reductions. Despite the trial miss, Theravance remains optimistic about Yupelri's future opportunities, a product which generated $202.1 million in sales in 2022.
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Theravance Biopharma announced results from its Phase 4 PIFR-2 study of YUPELRI® (revefenacin) for severe to very severe COPD, which did not meet its primary endpoint of statistically significant difference in lung function improvement compared to Spiriva® HandiHaler. Despite this, YUPELRI demonstrated an efficacy and safety profile consistent with previous studies, and the company sees continued growth opportunities for the product as an important COPD maintenance care option. Further data analysis from the study is anticipated to be shared in the future.
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
Theravance Biopharma, Inc. announced the appointment of Jeremy Grant, Special Advisor to Irenic Capital Management LP, to its Board of Directors. This appointment follows a cooperation agreement with Irenic Capital, and Theravance reaffirmed its commitment to return all excess capital to shareholders and maximize shareholder value. The company plans to maintain a disciplined approach to expense management, having already returned over $300 million to shareholders and reduced shares outstanding by approximately 35% since mid-2022.
Theravance, under pressure from activist investor, cuts back research, trims staff
Theravance Biopharma is implementing significant restructuring, including cutting research spending, discontinuing JAK inhibitor research, and laying off nearly a fifth of its workforce. These actions are partly in response to pressure from activist investor Irenic Capital Management, which has called for special dividends and changes to company leadership. Theravance also announced plans to return an additional $75 million to shareholders and appointed a new independent director to its board.
Theravance, flush with royalty cash, buys shares from GSK
Theravance Biopharma is buying back all 9.6 million shares owned by GSK as part of a $250 million stock repurchase plan, aiming to pivot away from legacy respiratory products developed in their long-standing collaboration. This move follows Theravance's sale of royalty rights from GSK’s blockbuster asthma drug Trelegy Ellipta to Royalty Pharma for $1.1 billion upfront. The share buyback will further unwind the 2002 collaboration with GSK, which had resulted in marketed drugs like Breo, Anoro, and Trelegy.
